Lv4
660 积分 2023-08-03 加入
[PIK3CA gene mutations in Chinese women with HR+/HER2- breast cancer]
3天前
已完结
[Guidelines on clinical practice of molecular tests in non-small cell lung cancer in China (2024 version)]
13天前
已完结
[The trend of accurate pathology diagnosis of breast cancer]
23天前
已完结
Structural Variation Interpretation in the Genome Sequencing Era: Lessons from Cytogenetics
1个月前
已完结
[Guidelines for diagnosis and treatment of advanced breast cancer in China (2024 edition)]
2个月前
已完结
[Guidelines on tests of PIK3CA mutation in breast cancer in China (2025 version)]
2个月前
已完结
[Consensus on the molecular residual disease testing in solid tumor]
5个月前
已完结
Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer
8个月前
已完结
AKT1 gene amplification as a biomarker of treatment response in ovarian cancer: Mounting evidence of a therapeutic target
8个月前
已完结
The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts
8个月前
已完结
皖公网安备34019202002308
